General Announcement::Press Release

Issuer & Securities

Issuer/ Manager
BIOCON BIOLOGICS GLOBAL PLC
Securities
BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB
BIOCONBIO US$800M6.67%N291009R - USG11185AA61 - KSEB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
16-Jul-2025 02:37:39
Status
New
Announcement Sub Title
Press Release
Announcement Reference
SG250716OTHRT81I
Submitted By (Co./ Ind. Name)
Biocon Biologics Limited / Akhilesh Nand
Designation
Company Secretary
Effective Date and Time of the event
16/07/2025 00:05:00
Description (Please provide a detailed description of the event in the box below)
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty , the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States.

Attachments

BBL_SGX_Kirsty_FDA_15072025.pdf
Total size =505K